Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,dividendsPaid,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ZEG.DE,-16128000000,1312770048,1810000000,,764000000,17000000,550000000,3156000000,6035000000,1197000000,1197000000,-128000000,-279000000,,,,214000000,8220000000,7023000000,2185000000,-433000000,,550000000,550000000,20006000000,7980000000,57948000000,15676000000,1582000000,73641000000,328000000,41000000,5335000000,9636000000,11798000000,2033000000,4412000000,15567000000,22222000000,3723000000,3042000000,2033000000,9031000000,27274000000,1120000000,62000000,6842000000,25598000000,4762000000,16840000000,97000000.0,0.0,-236000000.0,7284000000.0,7289000000.0,-353000000.0,4000000.0,7960000000.0,15000000.0,892000000.0,753000000.0,3000000.0,1000000.0,-58000000.0,-288000000.0,,,,5052000000,en-US,US,EQUITY,False,Delayed Quote,EUR,0.92957276,99.52 - 100.18,98.97,99.87,99.99,300,300,finmb_336774,XETRA,USD,13185,4648,21.949997,0.28162685,77.94 - 102.68,-2.790001,-0.027171806,77.94,102.68,2.8,39.32677,0.0282914,2.54,7200000,10.998,98.52286,1.3671417,0.013876392,91.67078,8.219223,2,"ASTRAZENECA PLC  DL-,25",AstraZeneca PLC,99.89,1630581443,0.91999817,99.55,100.18,99.52,3199,REGULAR,GER,de_market,0.089660235,131132596224,9.082561,15,Europe/Berlin,CEST,False,False,0,0.19,,,102.68,77.94,98.52,91.67,13.19k,4.65k,1.31B,,1.31B,0.32%,46.83%,,,,,,2.37,2.35%,2.80,2.83%,3.53,99.04%,,"Aug 12, 2021",2:1,"Jul 27, 2015","Dec 31, 2020","Jun 30, 2021",12.77%,13.41%,3.70%,25.67%,29.53B,22.51,31.00%,21.37B,6.64B,3.77B,2.54,-27.20%,15.63B,11.91,29.89B,190.47,1.23,11.00,6.45B,5.87B,Value,CB2 0AA,Healthcare,76100,8,1,"AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 20 3749 5000,1,1609372800,1625097600,8,United Kingdom,http://www.astrazeneca.com,86400,7,1 Francis Crick Avenue,Drug Manufacturers—General,Cambridge Biomedical Campus
t-1,ZEG.DE,-17682000000,1312770048,1700000000,,1608000000,16000000,1561000000,2998000000,5463000000,1169000000,1169000000,-404000000,-303000000,,,,46000000,7320000000,6151000000,1857000000,439000000,,1562000000,1561000000,20347000000,7976000000,50480000000,14430000000,1869000000,64926000000,328000000,64000000,4089000000,9630000000,11765000000,2037000000,4170000000,7636000000,21513000000,3506000000,2351000000,2037000000,8849000000,18735000000,1060000000,129000000,6628000000,18873000000,4278000000,16496000000,749000000.0,0.0,555000000.0,-244000000.0,-2731000000.0,1210000000.0,5000000.0,-309000000.0,-67000000.0,1934000000.0,742000000.0,24000000.0,-23000000.0,-1579000000.0,-220000000.0,-2469000000.0,,,-2778000000,en-US,US,EQUITY,False,Delayed Quote,EUR,0.92957276,99.52 - 100.18,98.97,99.87,99.99,300,300,finmb_336774,XETRA,USD,13185,4648,21.949997,0.28162685,77.94 - 102.68,-2.790001,-0.027171806,77.94,102.68,2.8,39.32677,0.0282914,2.54,7200000,10.998,98.52286,1.3671417,0.013876392,91.67078,8.219223,2,"ASTRAZENECA PLC  DL-,25",AstraZeneca PLC,99.89,1630581443,0.91999817,99.55,100.18,99.52,3199,REGULAR,GER,de_market,0.089660235,131132596224,9.082561,15,Europe/Berlin,CEST,False,False,0,0.19,,,102.68,77.94,98.52,91.67,13.19k,4.65k,1.31B,,1.31B,0.32%,46.83%,,,,,,2.37,2.35%,2.80,2.83%,3.53,99.04%,,"Aug 12, 2021",2:1,"Jul 27, 2015","Dec 31, 2020","Jun 30, 2021",12.77%,13.41%,3.70%,25.67%,29.53B,22.51,31.00%,21.37B,6.64B,3.77B,2.54,-27.20%,15.63B,11.91,29.89B,190.47,1.23,11.00,6.45B,5.87B,Value,CB2 0AA,Healthcare,76100,8,1,"AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 20 3749 5000,1,1609372800,1625097600,8,United Kingdom,http://www.astrazeneca.com,86400,7,1 Francis Crick Avenue,Drug Manufacturers—General,Cambridge Biomedical Campus
t-2,ZEG.DE,-17170000000,1312770048,1881000000,,1167000000,16000000,1012000000,3467000000,5894000000,546000000,546000000,-404000000,-3000000,,,,162000000,7410000000,6864000000,1516000000,621000000,,1005000000,1012000000,20947000000,7971000000,51091000000,15622000000,5849000000,66729000000,328000000,99000000,6442000000,10491000000,11845000000,881000000,4284000000,7832000000,20307000000,3438000000,1566000000,881000000,8917000000,19544000000,1192000000,42000000,5651000000,19804000000,4024000000,2350000000,475000000.0,1721000000.0,138000000.0,-2229000000.0,-2210000000.0,255000000.0,19000000.0,-248000000.0,26000000.0,1798000000.0,667000000.0,44000000.0,-23000000.0,-558000000.0,-363000000.0,-2469000000.0,-621000000.0,-739000000.0,-763000000,en-US,US,EQUITY,False,Delayed Quote,EUR,0.92957276,99.52 - 100.18,98.97,99.87,99.99,300,300,finmb_336774,XETRA,USD,13185,4648,21.949997,0.28162685,77.94 - 102.68,-2.790001,-0.027171806,77.94,102.68,2.8,39.32677,0.0282914,2.54,7200000,10.998,98.52286,1.3671417,0.013876392,91.67078,8.219223,2,"ASTRAZENECA PLC  DL-,25",AstraZeneca PLC,99.89,1630581443,0.91999817,99.55,100.18,99.52,3199,REGULAR,GER,de_market,0.089660235,131132596224,9.082561,15,Europe/Berlin,CEST,False,False,0,0.19,,,102.68,77.94,98.52,91.67,13.19k,4.65k,1.31B,,1.31B,0.32%,46.83%,,,,,,2.37,2.35%,2.80,2.83%,3.53,99.04%,,"Aug 12, 2021",2:1,"Jul 27, 2015","Dec 31, 2020","Jun 30, 2021",12.77%,13.41%,3.70%,25.67%,29.53B,22.51,31.00%,21.37B,6.64B,3.77B,2.54,-27.20%,15.63B,11.91,29.89B,190.47,1.23,11.00,6.45B,5.87B,Value,CB2 0AA,Healthcare,76100,8,1,"AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 20 3749 5000,1,1609372800,1625097600,8,United Kingdom,http://www.astrazeneca.com,86400,7,1 Francis Crick Avenue,Drug Manufacturers—General,Cambridge Biomedical Campus
t-3,ZEG.DE,-20129000000,1312770048,1481000000,,853000000,1423000000,648000000,2738000000,5217000000,1282000000,1282000000,-284000000,-324000000,,,,202000000,6578000000,5296000000,1361000000,-429000000,,651000000,648000000,20613000000,7952000000,50494000000,12195000000,1942000000,64112000000,328000000,37000000,1876000000,10527000000,11711000000,2039000000,4047000000,8072000000,18942000000,3243000000,2195000000,2039000000,8360000000,18166000000,1215000000,374000000,6000000000,20542000000,3683000000,13406000000,239000000.0,0.0,-580000000.0,2423000000.0,1243000000.0,525000000.0,2000000.0,2489000000.0,4000000.0,1822000000.0,732000000.0,6000000.0,-8000000.0,-83000000.0,-228000000.0,-1174000000.0,-621000000.0,-739000000.0,-776000000,en-US,US,EQUITY,False,Delayed Quote,EUR,0.92957276,99.52 - 100.18,98.97,99.87,99.99,300,300,finmb_336774,XETRA,USD,13185,4648,21.949997,0.28162685,77.94 - 102.68,-2.790001,-0.027171806,77.94,102.68,2.8,39.32677,0.0282914,2.54,7200000,10.998,98.52286,1.3671417,0.013876392,91.67078,8.219223,2,"ASTRAZENECA PLC  DL-,25",AstraZeneca PLC,99.89,1630581443,0.91999817,99.55,100.18,99.52,3199,REGULAR,GER,de_market,0.089660235,131132596224,9.082561,15,Europe/Berlin,CEST,False,False,0,0.19,,,102.68,77.94,98.52,91.67,13.19k,4.65k,1.31B,,1.31B,0.32%,46.83%,,,,,,2.37,2.35%,2.80,2.83%,3.53,99.04%,,"Aug 12, 2021",2:1,"Jul 27, 2015","Dec 31, 2020","Jun 30, 2021",12.77%,13.41%,3.70%,25.67%,29.53B,22.51,31.00%,21.37B,6.64B,3.77B,2.54,-27.20%,15.63B,11.91,29.89B,190.47,1.23,11.00,6.45B,5.87B,Value,CB2 0AA,Healthcare,76100,8,1,"AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",Cambridge,44 20 3749 5000,1,1609372800,1625097600,8,United Kingdom,http://www.astrazeneca.com,86400,7,1 Francis Crick Avenue,Drug Manufacturers—General,Cambridge Biomedical Campus
